AbbVie announced today that its drug therapy upadacitinib (also known as RINVOQ®) met its primary and secondary endpoints when administered alone or as a combination therapy for treatment of moderate to severe active lupus in individuals receiving standard disease therapies. The drug is advancing to Phase 3 clinical trial for treatment of lupus. RINVOQ is already approved for the treatment of other autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, and eczema.
In the SLEek Phase 2 trial of RINVOQ, the drug was given alone to trial participants in a 30-mg dose or as a combination therapy with elsubrutinib (60-mg dose) at week 24. At week 48, both groups exhibited improved active disease.
Continue to follow the Lupus Foundation of America for updates on RINVOQ as well as other lupus clinical trials.
This post was originally published on this site